Emine Elif ALTUNTAŞ, Kasım DURMUŞ, Aynur ENGİN, Zekiye HASBEK

Development of parotitis after radioiodine therapy in a differentiated thyroid cancer patient: Case report

Bu makalede, diferansiye tiroid papiller karsinom nedeniyle radyoaktif iyot (RAI-131I) tedavisi verilen ve tedavinin 24. saatinde parotitis gelişen 51 yaşındaki kadın hastayı sunduk. 131I ile yüksek doz ablasyon tedavi sonrası siyaloadenit, düşük klinik izlem ile birlikte rölatif olarak sık bir komplikasyondur. Radyasyon hastalığı nedeniyle tat alma bozukluğu veya kaybı, ve bulantı ve kusma diğer en sık yan etkilerdir. Kserostomi hastaların morbiditesini artıran önemli bir problemdir. Bu nedenle, semptomatik hastalarda serum amilaz d üzeylerinin takibi, kserostominin önlenmesi için önemlidir. Bakteriyel ve viral etkenler dışında radyasyonun da sialadenit yapabileceği dikkate alınarak, radyoaktif iyot sonrası gelişen tükürük bezi büyümesinin, radyasyon komplikasyonu olduğunu söylemeden önce, klinik ve laboratuvar bulgularla birlikte diğer parotit olasılıklarının da ekarte edilmesi gereklidir. Bunun yanısıra, gerek acil servislerde gerekse Kulak Burun Boğaz (KBB) departmanlarında ağız kuruluğu ile başvuran hastalarda, hikayede mutlaka RAI tedavi öyküsünün de sorgulanması önemlidir.

Diferansiye tiroid kanser hastasında radyoiyot te- davisi sonrası parotit gelişimi: Olgu sunumu

In this article, we report a 51 years old female patient treated with radioactive iodine (RAI-131I) treatment for thyroid papillary carcinoma and developing parotitis on the 24 hour following treatment. Siaload enitis after high dose ablative therapy with 131I is a relatively common complication with a low clinical impression. Taste alteration or loss, and nausea and vomiting due to radiation sickness are the other most frequent side effects. Xerostomia is an important problem increasing morbidity of the patients. For this reason, it is important to prevent xerostamia by following serum amylase levels in symptomatic patients. By taking into account that not only bacterial and viral factors but also radiation may cause sialoadenitis, one has to rule out other parotisis possibilities by clinical and laboratory findings before claiming that salivary gland enlargement developing after radioiodine is a complication of radiation. Moreover, history of RAI treatment should be given importance in patients applying either to emergency services or to Ear Nose Throat and Infectious Diseases Department with dry mouth.

PDF

___

Mazzaferri EL. The Diagnosis and imaging of Thyroid Cancer. In: Amdur JA, Mazzaferri EL, editors. Essentials of thyroid cancer management. Springer Science+Business Media, Inc. 2005; p: 39-120.
Almeida JP, Sanabria AE, Lima EN, Kowalski LP. Late side effects of radi- oactive iodine on salivary gland func- tion in pa-tients with thyroid cancer. Head Neck 2011; 33: 686-90.
Lee HN, An JY, Lee KM, Kim EJ, Choi WS, Kim DY. Salivary gland dysfunction after radioactive iodine (I- 131) therapy in patients following total thyroid-ectomy: emphasis on radioac- tive iodine therapy dose. Clin Imaging 2015; S0899-707: 324-6.
Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioio- dine therapy for thy-roid cancer. Clin Oncol (R Coll Radiol) 2007; 19: 83-6.
An YS, Yoon JK, Lee SJ, Song HS, Yoon SH, Jo KS. Symptomatic late- onset sialadenitis after radioiodine therapy in thy-roid cancer. Ann Nucl Med 2013; 27: 386-91.
Prendes BL, Orloff LA, Eisele DW. Therapeutic sialendoscopy for the management of radioiodine sialadeni- tis. Arch Oto-laryngol Head Neck Surg 2012; 138: 15-9.
Mandel SJ, Mandel L. False-positive xerostomia following radioactive io- dine treatment: case report. Oral Surg Oral Med Oral Pathol Oral Radiol En- dod 2007; 103: e43-7.
Jeong SY, Kim HW, Lee SW, Ahn BC, Lee J. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms. Thy- roid 2013; 23: 609-16.
Mandel SJ, Mandel L. Radioac-tive iodine and the salivary glands. Thy- roid 2003; 13: 265-71.
Solans R, Bosch JA, Galofré P, Porta F, Roselló J, Selva-O'Callagan A, Vi- lardell M. Salivary and lacrimal gland dys-function (sicca syndrome) after radioiodine therapy. J Nucl Med 2001; 42: 738-43.
Rosário PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thy- roid remnant ablation with 131I is as- sociated with lowered radio-toxicity. J Nucl Med 2008; 49: 1776-82.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J, Wiersinga W. Euro- pean consensus for the management of pa-tients with differentiated thyroid carcinoma of the follicular epi- thelium. Eur J Endocrinol 2006; 154: 787-803.